Trump Cancels $766M Moderna Deal for Pandemic Flu Vaccine

---

Full Story

The Trump administration has terminated a $766 million contract with Moderna Inc. to develop a vaccine for pandemic influenza, including H5N1 bird flu. The decision, announced recently, halts funding for a key public health initiative. This move has sparked debate over the administration’s health priorities.

The contract aimed to bolster preparedness for potential influenza outbreaks. Moderna had been working on vaccines to counter emerging viral threats.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 39% | Right 26% | Center 29% | Unrated 6%

The Context

The cancellation reflects a shift in federal health funding priorities. The administration has not detailed its reasons for ending the contract.

H5N1 bird flu remains a global health concern due to its high mortality rate. Past outbreaks have prompted significant investment in vaccine development.

Moderna’s vaccine program was part of broader U.S. pandemic preparedness efforts. The cancellation could delay progress in addressing future flu threats.

Supporters of the decision argue it frees up funds for other health initiatives. Critics warn it undermines readiness for potential pandemics.

The move has raised questions about the administration’s long-term health strategy. Experts stress the importance of sustained investment in vaccine research.

The cancellation may affect Moderna’s research timeline and resource allocation. Other companies may step in to fill the funding gap.